News | March 14, 2023
Pfizer acquires Seagen for US$ 43 billion to battle cancer
Proposed combination enhances Pfizer’s position as a leading company in oncology
Proposed combination enhances Pfizer’s position as a leading company in oncology
Twelve hospitals across India will be part of the network which will support the trial in India
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Qure.ai is scaling-up the integration of its AI-powered chest x-ray interpretation tool that can benefit early and easy detection of lung diseases including lung cancer.
To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform
Subscribe To Our Newsletter & Stay Updated
